{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:43:46Z","timestamp":1776840226064,"version":"3.51.2"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eosinophilic pneumonia (EP) is an uncommon, idiopathic interstitial lung disease distinguished by the atypical accumulation of eosinophils within the pulmonary parenchyma and airways. The condition often presents insidiously and is frequently overlooked or misdiagnosed; pharmacological agents are among the acknowledged precipitants of this disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective pharmacovigilance investigation. We utilized the FAERS and Vigibase databases to detect adverse reactions associated with drug-related EP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified a total of 15,374 cases of drug-induced EP in FAERS. The incidence was highest, at 24.1%, among individuals aged 45 to 64\u202fyears, with 35.4% of the affected patients requiring hospitalization. In terms of the numerical composition of PTs, pneumonitis was the most predominant PT. Although the proportion of PTs varied for each drug and pneumonitis remained the most common, antibacterials exhibited a higher prevalence of \u201ceosinophilic pneumonia\u201d and \u201cpulmonary eosinophilia.\u201d Notable observations include significant signal variations between the two databases for certain drugs, yet all positive signal drugs identified by FAERS can be confirmed by Vigibase. Initial screening identified 302 suspect drugs; following disproportionality filtering, univariate analysis, and lasso shrinkage, 56 agents were retained. Nivolumab was the most frequently reported drug (1,377 reports), followed by pembrolizumab (1,070 reports) and daptomycin (758 reports), with daptomycin exhibiting the most significant statistical signal in FAERS. Time-to-onset analysis indicated that EP typically manifested early. Multivariable modeling identified higher body weight, advancing age, and polypharmacy as associated factors. The drugs most strongly associated with EP were daptomycin (OR 12.50, 95% CI 9.40\u201316.75), durvalumab (OR 5.17, 95% CI 3.74\u20137.14), fam-trastuzumab deruxtecan (OR 4.86, 95% CI 3.32\u20137.04), idelalisib (OR 4.74, 95% CI 3.13\u20137.07), and osimertinib (OR 3.21, 95% CI 2.11\u20134.79).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The early discontinuation of the offending drug, timely initiation of corticosteroid therapy, and multidisciplinary collaboration are fundamental to achieving improved outcomes in cases of drug-induced eosinophilic pneumonia. This study offers substantial real-world evidence to facilitate the early identification and optimal management of eosinophilic pneumonia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1788843","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:46:52Z","timestamp":1776836812000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-induced eosinophilic pneumonia: a real-world data mining study of the FAERS and Vigibase database reveals potential safety signals and risk patterns"],"prefix":"10.3389","volume":"13","author":[{"given":"Jing","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Lianyungang Hospital of Xuzhou Medical University","place":["Lianyungang, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangrong","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1164\/rccm.201710-1967CI","article-title":"Acute eosinophilic pneumonia. Causes, diagnosis, and management","volume":"197","author":"De Giacomi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"9095275","DOI":"10.1155\/2018\/9095275","article-title":"Eosinophils from physiology to disease: a comprehensive review","volume":"2018","author":"Ramirez","year":"2018","journal-title":"Biomed Res Int"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"G1175","DOI":"10.1152\/ajpgi.00313.2012","article-title":"Tissue remodeling in eosinophilic esophagitis","volume":"303","author":"Cheng","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1398-9995.2004.00492.x","article-title":"Elevated interleukin-18 levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia","volume":"59","author":"Katoh","year":"2004","journal-title":"Allergy"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.chest.2017.03.001","article-title":"Acute eosinophilic pneumonia: correlation of clinical characteristics with underlying cause","volume":"152","author":"De Giacomi","year":"2017","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1001\/jama.292.24.2997","article-title":"Acute eosinophilic pneumonia among US military personnel deployed in or near Iraq","volume":"292","author":"Shorr","year":"2004","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3346\/jkms.2016.31.2.247","article-title":"Clinical characteristics and factors influencing the occurrence of acute eosinophilic pneumonia in Korean military personnel","volume":"31","author":"Yoon","year":"2016","journal-title":"J Korean Med Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jiac.2016.09.001","article-title":"Eosinophilic pneumonia caused by daptomycin: six cases from two institutions and a review of the literature","volume":"23","author":"Hirai","year":"2017","journal-title":"J Infect Chemother"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1179\/acb.2009.056","article-title":"Minocycline induced eosinophilic pneumonia: case report and review of literature","volume":"64","author":"Klerkx","year":"2009","journal-title":"Acta Clin Belg"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.therap.2018.03.005","article-title":"Eosinophilic pneumonia induced by non-steroidal anti inflammatory drugs: an underestimated risk","volume":"73","author":"Krabansky","year":"2018","journal-title":"Therapie"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"ofad 414","DOI":"10.1093\/ofid\/ofad414","article-title":"Pharmacovigilance study on eosinophilic pneumonia induced by anti-MRSA agents: analysis based on the FDA adverse event reporting system","volume":"10","author":"Okada","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"bbab 347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"942237","DOI":"10.3389\/fmed.2022.942237","article-title":"Case report: eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis","volume":"9","author":"Zhu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1277734","DOI":"10.3389\/fimmu.2023.1277734","article-title":"Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00115-008-2437-y","article-title":"Drug-induced eosinophilic pneumonia","volume":"79","author":"Schelhorn","year":"2008","journal-title":"Nervenarzt"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e13509","DOI":"10.7759\/cureus.13509","article-title":"Daptomycin-induced acute eosinophilic pneumonia","volume":"13","author":"Portalatin","year":"2021","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13756-016-0158-8","article-title":"Daptomycin-induced eosinophilic pneumonia a systematic review","volume":"5","author":"Uppal","year":"2016","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.medcli.2022.03.017","article-title":"Clinical characteristics, management, and outcome of eosinophilic pneumonia associated with daptomycin","volume":"160","author":"Wu","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s15010-024-02349-z","article-title":"Francisci, Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series","volume":"52","author":"Gidari","year":"2024","journal-title":"Infection"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/iid3.238","article-title":"A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient","volume":"7","author":"Jodai","year":"2019","journal-title":"Immun Inflamm Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"11695","DOI":"10.1073\/pnas.0601347103","article-title":"Regulation of T cell activation and tolerance by PDL2","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e20240110","DOI":"10.36416\/1806-3756\/e20240110","article-title":"Drug-induced lung disease: a narrative review","volume":"50","author":"Bridi","year":"2024","journal-title":"J Bras Pneumol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/1759-7714.13848","article-title":"Immune checkpoint inhibitors-induced eosinophilic pneumonia: a case report","volume":"12","author":"Hara","year":"2021","journal-title":"Thorac Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1615531","DOI":"10.3389\/fimmu.2025.1615531","article-title":"Successful management of chronic eosinophilic pneumonia triggered by immune checkpoint inhibitor: a case report and literature review","volume":"16","author":"Suzuki","year":"2025","journal-title":"Front Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e70679","DOI":"10.1002\/cam4.70679","article-title":"Exploring the dynamics of immune checkpoint inhibitor-induced eosinophilia in advanced\/metastatic melanoma: a comprehensive retrospective analysis","volume":"14","author":"Diamantopoulos","year":"2025","journal-title":"Cancer Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung Cancer: benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1111\/cas.14609","article-title":"Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy","volume":"111","author":"Udagawa","year":"2020","journal-title":"Cancer Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1016\/j.cllc.2017.10.008","article-title":"Lung toxicity in non-small-cell lung Cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature","volume":"19","author":"Pellegrino","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12890-017-0519-y","article-title":"Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease","volume":"17","author":"Nitawaki","year":"2017","journal-title":"BMC Pulm Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.21037\/tlcr-20-564","article-title":"Safety of lorlatinib following alectinib induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series","volume":"10","author":"Myall","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/j.cllc.2020.06.021","article-title":"Successful drug rechallenge following severe acute alectinib-induced interstitial lung disease in a patient with advanced ALK rearranged lung adenocarcinoma","volume":"22","author":"Gadotti","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1177\/1078155220961557","article-title":"Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease","volume":"27","author":"Huang","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","author":"Barr","year":"2016","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1002\/ijc.29887","article-title":"Mtor inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm","volume":"138","author":"Willemsen","year":"2016","journal-title":"Int J Cancer"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11523-019-00656-2","article-title":"Prospective study of drug-induced interstitial lung disease in advanced breast cancer patients receiving everolimus plus exemestane","volume":"14","author":"Willemsen","year":"2019","journal-title":"Target Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1097\/JTO.0b013e3181ba20b1","article-title":"Characterization of pneumonitis in patients with advanced non small cell lung cancer treated with everolimus (RAD001)","volume":"4","author":"White","year":"2009","journal-title":"J Thorac Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"272","DOI":"10.36401\/JIPO-24-12","article-title":"Updates in drug-related pneumonitis due to targeted oncologic therapies","volume":"7","author":"Chan","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/OP.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with Trastuzumab Deruxtecan use in human epidermal growth factor receptor 2 expressing metastatic breast Cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.3390\/curroncol30090582","article-title":"Managing the risk of lung toxicity with trastuzumab deruxtecan (T-DXd): a Canadian perspective","volume":"30","author":"Henning","year":"2023","journal-title":"Curr Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1155\/2009\/282540","article-title":"Amiodarone pulmonary toxicity","volume":"16","author":"Wolkove","year":"2009","journal-title":"Can Respir J"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00392-010-0181-3","article-title":"Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?","volume":"99","author":"Schwaiblmair","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jccase.2022.10.012","article-title":"Diffuse alveolar hemorrhage and acute eosinophilic pneumonia: a rare form of amiodarone pulmonary toxicity diagnosed by bronchoalveolar lavage","volume":"27","author":"Anai","year":"2023","journal-title":"J Cardiol Cases"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1788843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:46:53Z","timestamp":1776836813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1788843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":53,"alternative-id":["10.3389\/fmed.2026.1788843"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1788843","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1788843"}}